View Exam | PowerPak

1. Acute myeloid leukemia is a disease primarily associated with:

A. Ineffective hematopoiesis B. Renal failure C. Progressive cardiac decompensation D. High frequency of strokes E. Unsure

2. What is the prognostic categorization for an AML patient with normal bone marrow cytogenetics?

A. Poor risk B. Intermediate risk C. Favorable risk D. Indeterminate risk E. Unsure

3. What is an appropriate initial treatment for an 84 year old bedbound patient with advanced dementia who has a concurrent new diagnosis of AML?

A. 7+3 induction chemotherapy with cytarabine and idarubicin B. Enasidenib C. Allogeneic stem cell transplantation D. Supportive care only E. Unsure

4. A patient with newly diagnosed AML is about to begin induction therapy for AML with 7+3 (cytarabine and idarubicin). What therapies should be available or prescribed as she begins treatment?

A. Antiemetics with a serotonin antagonist-based regimen B. Red cell and platelet transfusions C. Antibiotics and antifungals for neutropenic fever treatment D. All of the above E. Unsure

5. Which adverse effect(s) are NOT associated with midostaurin therapy?

A. Nausea and vomiting B. Pneumonitis C. Elevated bilirubin D. Hyperglycemia E. Unsure

6. Which of the following interactions should be avoided due to increased toxicity related to the anticancer agent?

A. Gemtuzumab ozogamicin and erythromycin B. Midostaurin and voriconazole C. Enasidenib and a high fat meal D. Liposomal daunorubicin/cytarabine and amiodarone E. Unsure

7. SL is a 77-year-old man admitted for relapsed AML evaluation and management. He begins enasidenib 100 mg PO daily and, the next day, he complains of shortness of breath with hypoxia, fever, and has infiltrates and a mild pleural effusion on chest X-ray. His creatinine is mildly elevated. Which of the following therapies is most critical to be initiated?

A. Dexamethasone B. Rasburicase C. Cefepime D. Furosemide E. Unsure

8. You are educating the inpatient leukemia team on the role and place in therapy of the novel formulation of liposomal daunorubicin and cytarabine. In thinking about the similarities and differences between the new product and conventional 7+3, which of the following statements is correct?

A. The liposomal formulation should only be used for induction and, if needed, reinduction treatment B. Complete response rates and overall survival were superior with the liposomal formulation C. Cardiotoxicity rates and severity are lower with the liposomal formulation due to reduced drug penetration D. Generalized/total body edema is more common and more severe with the liposomal formulation E. Unsure

9. A physician you work with has an 82-year-old patient with newly diagnosed acute myeloid leukemia and wants your input on treatment. She is considering induction with gemtuzumab ozogamicin versus conventional 7+3. What is the optimal response?

A. “Gemtuzumab ozogamicin should not be used in this patient, as the elderly have a greater risk of treatment-related death” B. “If you're going to use it for induction, it must be in combination with daunorubicin and cytarabine” C. “I would avoid using acetaminophen as a pre-medication, as it will increase the risk of hepatotoxicity” D. “It's a reasonable treatment option, but what is the status of CD33 staining on their marrow?” E. Unsure

Evaluation Questions

10. How confident are you in your recommendation for therapy for the patient in question 7 (SL is a 77-year-old man admitted for relapsed acute myeloid leukemia)?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Acute myeloid leukemia is a disease primarily associated with:

2. What is the prognostic categorization for an AML patient with normal bone marrow cytogenetics?

3. What is an appropriate initial treatment for an 84 year old bedbound patient with advanced dementia who has a concurrent new diagnosis of AML?

4. A patient with newly diagnosed AML is about to begin induction therapy for AML with 7+3 (cytarabine and idarubicin). What therapies should be available or prescribed as she begins treatment?

5. Which adverse effect(s) are NOT associated with midostaurin therapy?

6. Which of the following interactions should be avoided due to increased toxicity related to the anticancer agent?

8. You are educating the inpatient leukemia team on the role and place in therapy of the novel formulation of liposomal daunorubicin and cytarabine. In thinking about the similarities and differences between the new product and conventional 7+3, which of the following statements is correct?

9. A physician you work with has an 82-year-old patient with newly diagnosed acute myeloid leukemia and wants your input on treatment. She is considering induction with gemtuzumab ozogamicin versus conventional 7+3. What is the optimal response?

Evaluation Questions

10. How confident are you in your recommendation for therapy for the patient in question 7 (SL is a 77-year-old man admitted for relapsed acute myeloid leukemia)?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Acute myeloid leukemia is a disease primarily associated with:

2. What is the prognostic categorization for an AML patient with normal bone marrow cytogenetics?

3. What is an appropriate initial treatment for an 84 year old bedbound patient with advanced dementia who has a concurrent new diagnosis of AML?

4. A patient with newly diagnosed AML is about to begin induction therapy for AML with 7+3 (cytarabine and idarubicin). What therapies should be available or prescribed as she begins treatment?

5. Which adverse effect(s) are NOT associated with midostaurin therapy?

6. Which of the following interactions should be avoided due to increased toxicity related to the anticancer agent?

8. You are educating the inpatient leukemia team on the role and place in therapy of the novel formulation of liposomal daunorubicin and cytarabine. In thinking about the similarities and differences between the new product and conventional 7+3, which of the following statements is correct?

9. A physician you work with has an 82-year-old patient with newly diagnosed acute myeloid leukemia and wants your input on treatment. She is considering induction with gemtuzumab ozogamicin versus conventional 7+3. What is the optimal response?

Evaluation Questions

10. How confident are you in your recommendation for therapy for the patient in question 7 (SL is a 77-year-old man admitted for relapsed acute myeloid leukemia)?

« Return to Activity

Customers who Purchased
this Activity also Purchased